Registered title, quoted from ClinicalTrials.gov
Risk Stratification and MRD-driven Maintenance for MM After ASCT
An open trial on multiple myeloma, registered on ClinicalTrials.gov. Led by Peking University People's Hospital; 2 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 3
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
- Lead sponsorPeking University People's Hospital北京大学人民医院BeijingHospital page
- Study siteFirst Affiliated Hospital of Harbin Medical University哈尔滨医科大学附属第一医院HarbinHospital page
- Study sitePeking Union Medical College Hospital北京协和医院BeijingHospital page
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT06697483, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 4
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (4 points)Hide the checklist
18 years to Not stated; sex: all
Registered eligibility fields
Newly diagnosed multiple myeloma with a history of a minimum of 4 cycles of induction therapy, have received high-dose therapy (HDT) and autologous stem cell transplantation (ASCT) within 12 months of the start of induction therapy, and be within 6 months of ASCT.
Inclusion criterion 1
Must have an Eastern Cooperative Oncology Group performance status score of 0, 1, or 2.
Inclusion criterion 3
ANC ≥ 1.0 x 10\^9/L, Hb ≥ 85 g/L PLT ≥ 75 x 10\^9/L (if BMPC < 50%) or PLT ≥ 50 x 10\^9/L (if BMPC ≥ 50%).
Inclusion criterion 5
a).TBIL<1.5 x upper limit of normal (ULN) (<3 x ULN in patients with Gilbert's syndrome); b).AST and ALT <3 x ULN.; c. Creatinine clearance ≥ 45mL/min.
Inclusion criterion 7
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; scans and measurable lesions; other conditions the trial excludes; pregnancy, breastfeeding and contraception.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06697483, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Newly diagnosed multiple myeloma with a history of a minimum of 4 cycles of induction therapy, have received high-dose therapy (HDT) and autologous stem cell transplantation (ASCT) within 12 months of the start of induction therapy, and be within 6 months of ASCT.
- Must have a partial response (PR) or better response before maintenance.
- Must have an Eastern Cooperative Oncology Group performance status score of 0, 1, or 2.
- This study allows for post-ASCT consolidation therapy.
- ANC ≥ 1.0 x 10\^9/L, Hb ≥ 85 g/L PLT ≥ 75 x 10\^9/L (if BMPC < 50%) or PLT ≥ 50 x 10\^9/L (if BMPC ≥ 50%).
- No active infection.
- a).TBIL<1.5 x upper limit of normal (ULN) (<3 x ULN in patients with Gilbert's syndrome); b).AST and ALT <3 x ULN.; c. Creatinine clearance ≥ 45mL/min.
Exclusion Criteria:
- Must not refractory or non-tolerate to lenalidomide in Arm A.
- Must not refractory or non-tolerate to lenalidomide and daratumumab in Arm B.
- Must not have progressed on multiple myeloma (MM) therapy before screening
- Chronic obstructive pulmonary disease (COPD) with FEV1 less than 50 % of predicted normal;
- Have known moderate or severe persistent asthma within the past 2 years or current uncontrolled asthma of any classification
- History of stroke or serious thrombotic event within 12 months prior to screening.
Quoted from ClinicalTrials.gov, NCT06697483, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT06697483, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.